Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
Future Oncol
; 11(3): 431-8, 2015.
Article
en En
| MEDLINE
| ID: mdl-25675124
ABSTRACT
AIM:
This multicenter study describes the effectiveness of eribulin in current practice. PATIENTS &METHODS:
In total, 78 patients with advanced metastatic breast cancer, previously treated with two or more chemotherapy lines were enrolled.RESULTS:
The median duration of response and disease stability were 7.5 (5.4-9.5) and 8.9 (6.2-11.6) months, respectively, with a clinical benefit (CB) at 6 months in 41% of patients. CB in visceral and nonvisceral metastases were 72.7 and 88.9%, respectively. Eribulin was active also in brain metastases, with 47% CB. The activity was shown in all biological subtypes. Toxicities were manageable.CONCLUSION:
Our study confirms the effectiveness of eribulin mesylate in the treatment of patients with metastatic breast cancer and two or more lines of chemotherapy, in particular in the good disease control at the different metastatic sites.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Furanos
/
Cetonas
/
Antineoplásicos
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Límite:
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Año:
2015
Tipo del documento:
Article
País de afiliación:
Italia